Skip to main content
    F

    Forte Biosciences Inc (FBRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $76.99
    +0.00 (+0.00%)

    Market Cap: $1.63B

    Last updated: Aug 27, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(21/38)
    Avg Surprise
    -70.34%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.78
    Range$-0.78 - $-0.78
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.00+22.3%
    60d ago$-1.00+22.3%
    30d ago$-1.00+22.3%
    7d ago$-0.93+16.2%
    Current$-0.78
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.11
    Range$-1.66 - $-0.40
    5 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Last 12 of 38 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-1.11$-1.66 - $-0.40--5--
    Sep 26EST
    		-$-0.78$-0.78 - $-0.78--1
    0
    1
    30d
    		-
    Jun 26
    Reported Aug 11
    		$-0.97$-1.08$-1.08 - $-0.50+10.19%Beat4
    2
    2
    30d
    		-1.0%
    Mar 26
    Reported May 11
    		$-1.24$-1.16$-1.27 - $-1.07-6.90%Miss4
    No revisions (30d)
    		+9.5%
    Dec 25
    Reported Mar 31
    		$-1.45$-1.15$-1.47 - $-0.80-26.36%Miss4
    2
    1
    30d
    		-23.9%
    Sep 25
    Reported Nov 14
    		$-0.99$-1.07$-1.19 - $-0.88+7.48%Beat4
    2
    1
    30d
    		+78.2%
    Jun 25
    Reported Aug 14
    		$-0.96$-1.11$-1.46 - $-0.56+13.51%Beat4
    No revisions (30d)
    		+85.8%
    Mar 25
    Reported May 15
    		$-1.37$-0.89$-1.07 - $-0.83-53.93%Miss3
    0
    1
    30d
    		+65.8%
    Dec 24
    Reported Mar 24
    		$-1.17$-0.14--735.71%Miss3
    0
    1
    30d
    		-515.8%
    Sep 24
    Reported Nov 14
    		$-4.54$-7.12$-7.50 - $-6.75+36.24%Beat2
    0
    1
    30d
    		-1646.2%
    Jun 24
    Reported Aug 14
    		$-6.75$-4.12$-4.12 - $-4.11-63.84%Miss3
    No revisions (30d)
    		-1507.1%
    Mar 24
    Reported May 13
    		$-4.00$-4.25$-4.26 - $-4.25+5.88%Beat2
    No revisions (30d)
    		-1622.7%
    Dec 23
    Reported Mar 18
    		$-0.19$-0.28$-0.28 - $-0.28+32.14%Beat1
    No revisions (30d)
    		+17.4%
    Sep 23
    Reported Nov 13
    		$-0.26N/A-+54.39%Beat--+94.2%

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-62.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    Beta2.65Avg VolumeN/A
    52-Week High$77.0052-Week Low$10.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$76.92
    SMA 20$76.83
    SMA 50$53.93
    SMA 200$32.54
    EMA 10$76.70
    EMA 20$73.62
    EMA 50$59.59
    EMA 200$35.74

    MACD

    Line: 5.67Signal: 7.38Hist: -1.71

    ADX

    ADX: 84.8+DI: 48.5-DI: 2.6

    Aroon & PSAR

    Aroon Up20.0
    Aroon DownN/A
    PSAR$77.19

    Bollinger Bands

    Upper Band$77.09
    Lower Band$76.56
    %B Position69%(Middle)
    Band Width0.81

    RSI (14-Day)

    Overbought
    84.4

    Momentum Oscillators

    Stoch %K95.9
    Stoch %D96.6
    Williams %R-4.2
    ROC (10d)0.2%
    Momentum0.13
    CCI (20d)116.1
    MFI (14d)77.0

    Volatility Measures

    ATR (14d)$1.16(1.5%)
    StdDev (20d)0.13
    Hist Vol2.3%(Low)

    Volume Flow

    VWAP$76.99
    OBV42.4M
    AD Line10.1M
    CMF (20d)0.051

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol RatioN/A
    VWMA (20d)$76.85

    Pivot Points

    R3$77.05
    R2$77.02
    R1$77.01
    Pivot Point$76.98
    S1$76.97
    S2$76.94
    S3$76.93

    Advanced Oscillators

    TSI69.25
    Ultimate Osc59.8
    KST866.55

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$38,000$0$0$0$6,000$0
    Cost of Revenue$0$0$-45,000$0$0$0$10,000$0$0$0$6,000$0
    Gross Profit$0$0$45,000$0$0$0$-10,000$0$0$0$-6,000$0
    Operating Expenses$24.60M$22.29M$24.72M$18.38M$11.58M$15.97M$7.38M$8.63M$12.82M$7.78M$6.38M$10.22M
    R&D$22.34M$20.32M$21.89M$15.20M$8.62M$12.54M$5.26M$5.87M$5.74M$4.32M$3.57M$6.37M
    SG&A$2.27M$1.97M$2.83M$3.18M$2.96M$3.43M$2.12M$2.76M$7.08M$3.45M$2.81M$3.85M
    Operating Income$-24,603,000$-22,439,000$-24,571,000$-18,383,000$-11,579,000$-16,124,000$-7,351,000$-8,629,000$-12,818,000$-7,804,000$-6,381,000$-10,216,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-23,138,000$-21,763,000$-22,720,000$-18,383,000$-11,249,000$-15,656,000$-6,848,000$-8,392,000$-12,818,000$-7,420,000$-5,872,000$-9,955,000
    Income Tax Expense$193,000$373,000$0$0$0$0$0$0$0$0$0$0
    Net Income$-23,331,000$-22,136,000$-24,788,000$-17,682,000$-11,249,000$-15,656,000$-7,155,000$-8,392,000$-12,511,000$-7,420,000$-5,872,000$-9,955,000
    EBITDA$-24,159,000$-21,751,000$-24,543,000$-18,372,000$-11,234,000$-15,883,000$-7,497,000$-8,373,000$-12,813,000$-7,417,000$-6,990,000$-9,952,000
    EBIT$-23,138,000$-21,763,000$-24,571,000$-18,383,000$-11,249,000$-15,656,000$-7,351,000$-8,392,000$-12,818,000$-7,420,000$-6,996,000$-9,955,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FBRX

    News

    Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition

    Argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, integrating the antibody candidate FB102 into its immunology pipeline. This move aligns with Argenx's Vision 2030 plan to expand its focus...

    Yahoo Finance•8/27/26•Bullish

    argenx Completes Acquisition of Forte Biosciences, Inc.

    argenx, a global immunology innovation company, has announced the successful completion of its acquisition of Forte Biosciences, Inc. This acquisition adds Forte's first-in-class anti-CD122 Antibody, FB102...

    Barchart.com•8/27/26•Neutral

    Forte Biosciences earnings on deck as argenx deal looms

    Forte Biosciences is set to report its second-quarter earnings, likely its last as an independent company before its $2.2 billion acquisition by argenx closes. While the financial results are expected to show little...

    Investing.com•8/23/26•Bullish

    What Forte Biosciences (FBRX) bankers see in $77 cash bid

    Forte Biosciences (FBRX) has filed an amendment to its Schedule 14D-9 regarding the $77 per share cash tender offer by argenx BV. The amendment clarifies that Forte's executive officers have not yet finalized...

    Stock Titan•8/21/26•Somewhat-Bullish

    Forte Biosciences (FBRX) cash tender clears antitrust

    Forte Biosciences (FBRX) has received antitrust clearance for a cash tender offer by Avena Merger Sub Inc., a subsidiary of argenx. The offer seeks to acquire all outstanding Forte common shares at $77.00 per share....

    Stock Titan•8/19/26•Somewhat-Bullish

    FBRX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -62.3%

    FBRX Competitors

    CompanyTicker
    Personalis IncPSNL
    Butterfly Network IncBFLY
    Zenas BioPharma, Inc. Common StockZBIO
    Nurix Therapeutics IncNRIX
    Healthcare Services Group IncHCSG
    Novavax IncNVAX
    Kestra Medical Technologies, Ltd. Common StockKMTS
    Sellas Life Sciences Group IncSLS

    Sector: Healthcare

    FBRX Analyst Ratings

    Consensus
    Hold
    Analysts
    5
    Strong Buy
    0
    Buy
    1
    Hold
    4
    Sell
    0
    Strong Sell
    0

    FBRX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -94.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.78
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    FBRX Earnings Date

    FBRX reports Nov 12, 2026. The date is estimated.

    FBRX ETF Holders

    GNG tracks 3 ETFs that hold FBRX. The largest weights:

    1. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    2. iShares Core S&P Total U.S. Stock Market ETF (ITOT), <0.01% of the fund
    3. Vanguard Extended Market Index Fund ETF Shares (VXF), <0.01% of the fund
    Open the ETF Stock Exposure tool for FBRX

    See insider activity

    Frequently Asked Questions About FBRX

    When does FBRX report earnings?

    Forte Biosciences Inc (FBRX) is expected to report earnings on Nov 12, 2026.

    Does FBRX pay dividends?

    Forte Biosciences Inc (FBRX) does not currently pay a regular dividend.

    What is FBRX's market cap?

    Forte Biosciences Inc (FBRX) has a market capitalization of $1.63B with a current stock price of $76.99.

    Related stocks

    Sector: Healthcare

    All stocks starting with F

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In